WEBULL
WebtradeDownload

Spyre Therapeutics (SYRE) Completes $350 Million Equity Offering, Is It Still A Bargain?

Simply Wall St · 2d ago

Spyre Therapeutics (SYRE) just raised about US$350.0 million through a follow on equity offering, selling 4,117,648 common shares at US$85 each, which represents a US$5.10 discount to the offer price.

Spyre Therapeutics now trades at US$80.10. Despite the recent follow-on offer and a share price return that fell 11.93% over the past 30 days and 20.08% over 90 days, momentum over the longer stretch has been strong. The year-to-date share price return of 161.94% and a 1-year total shareholder return of 260.16% point to investors reassessing both its risks and potential over time.

Scan how Spyre Therapeutics compares with other fast moving healthcare names by reviewing our hand picked list of 34 healthcare AI stocks.

Spyre Therapeutics now trades below both the follow-on offer price and the average analyst target, which leaves a wide gap between recent trading and published estimates. How far does fair value sit from here?

Most Popular Narrative: 33% Undervalued

Spyre Therapeutics is trading at $80.10 against a widely followed fair value estimate of about $120, which puts a lot of weight on how its IBD and autoimmune plan plays out over the next few years.

Positive Part A data from SPY001, SPY002 and SPY003 in ulcerative colitis and the move of all three into SKYLINE Part B across a large global site footprint could create a path to late stage IBD programs that, if successful, may expand Spyre Therapeutics revenue potential in the next decade.

The focus on combination efficacy gains in IBD of roughly 10 percentage points in clinical remission compared with existing drugs, in a market where a small group of therapies historically captures most revenue, means any successful Spyre Therapeutics regimen could concentrate prescribing and materially influence long run revenue and operating leverage.

See why 2 investors see Spyre Therapeutics as 33% undervalued.

Result: Fair Value of $120.08 (UNDERVALUED)

Still, the story around Spyre Therapeutics can change quickly if TL1A data underwhelms in broader autoimmune settings or if insider selling continues to weigh on investor confidence.

Find out about the key risks to this Spyre Therapeutics narrative.

Another View: Spyre Therapeutics Looks Expensive On Book Value

On the flip side of that $120 fair value story, Spyre Therapeutics trades on a P/B of 7.8x against a US Biotechs sector average of 1.9x and a peer group around 10.4x. That gap points to meaningful valuation risk if enthusiasm cools or book-based metrics start to matter more for this stock.

See what the numbers say about this price in more detail with our valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown. followed by a closer look at Spyre Therapeutics' relative valuation picture

NasdaqGS:SYRE P/B Ratio as at Oct 2026
NasdaqGS:SYRE P/B Ratio as at Oct 2026
.

Next Steps

Mixed signals around Spyre Therapeutics can feel confusing, so move quickly, review both the upside and downside, and judge the balance of 1 key reward and 5 important warning signs.

Looking for more investment ideas beyond Spyre Therapeutics?

If Spyre Therapeutics is on your radar, consider broadening your opportunity set by scanning other focused shortlists that can inform your next move and highlight additional directions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.